Global Venlafaxine Hydrochloride Extended-Release Capsules Market Size, Share and Trends Analysis Report, By Application (Depression, Anxiety, Panic Attacks, and Social Anxiety Disorder (Social Phobia)), Forecast Period (2022-2028)

The global venlafaxine hydrochloride extended-release capsules market is anticipated to grow at a  CAGR of 8.2% during the forecast period (2022-2028). Depression is the fourth most common disease in the globe, and it is anticipated to overtake diabetes and is currently the most common by 2030. However, in China, the medical management of depression remains underappreciated, with less than 20% of depressed patients receiving relevant medicine at all levels of hospital care and less than 20% of Chinese depressed patients obtaining relevant medication. Furthermore, occurrences of sadness and suicides caused by depression are occurring at a younger age (college, and even primary and secondary school students). According to the World Health Organization (WHO), more than 350 million people globally suffer from depression, with an 18% increase in the last decade. The number of persons suffering from depression in China is expected to reach 95 million by 2021.

 

Antidepressant medication is the mainstay of current depression treatment, which is augmented by psychotherapy or physical therapy. Antidepressants such as serotonin-norepinephrine reuptake inhibitors (SNRIs) are used to treat major depressive disorder and other mental diseases.

 

Venlafaxine was the first SNRI inhibitor to receive FDA approval. Under the brand name Effexor XR, it was first developed by Wyeth, a Pfizer subsidiary. In 1994, the FDA approved the immediate-release form of venlafaxine for the treatment of depression, and in 1997, the FDA approved the extended-release form of venlafaxine. The extended-release variant has a smoother onset of action and lower peak concentrations than the immediate-release form, resulting in fewer side effects.

 

Some major players in the market include Cipla Inc., Macleods Pharmaceuticals Ltd., Pfizer Inc., Zydus Lifesciences Ltd., and Teva Pharmaceutical Industries Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market.

 

Cipla Inc. offers VENLOR XR Capsules (Venlafaxine hydrochloride), Venlafaxine’s depressive action in humans is thought to be linked to its ability to potentiate neurotransmitter activity in the central nervous system (CNS). Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), block neuronal serotonin and nor-epinephrine re-uptake but not dopamine re-uptake. In vitro, venlafaxine and ODV show no affinity for muscarinic cholinergic, H1 histaminergic, or alpha1 adrenergic receptors. The anticholinergic, sedative, and cardiovascular effects found with other psychiatric medications are thought to be linked to pharmacologic activity at these receptors. Venlafaxine and ODV have no inhibitory action against monoamine oxidase (MAO).

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Cipla Inc., Macleods Pharmaceuticals Ltd., Pfizer Inc., Zydus Lifesciences Ltd., and Teva Pharmaceutical Industries Ltd., among others.

 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global Venlafaxine Hydrochloride Extended-Release Capsules Market Report by Segment

By Application

• Depression
• Anxiety
• Panic Attacks
• Social Anxiety Disorder (Social Phobia)

 

Global Venlafaxine Hydrochloride Extended-Release Capsules Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa